Strategic Family Wealth Counselors L.L.C. bought a new position in Pfizer Inc. (NYSE:PFE) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 175,608 shares of the biopharmaceutical company’s stock, valued at approximately $7,665,000. Pfizer comprises 8.7% of Strategic Family Wealth Counselors L.L.C.’s portfolio, making the stock its 2nd largest holding.
Several other institutional investors and hedge funds have also bought and sold shares of PFE. Home Federal Bank of Tennessee raised its position in shares of Pfizer by 0.8% during the 4th quarter. Home Federal Bank of Tennessee now owns 29,695 shares of the biopharmaceutical company’s stock valued at $1,297,000 after buying an additional 249 shares in the last quarter. Advocacy Wealth Management Services LLC raised its position in Pfizer by 48.2% in the 4th quarter. Advocacy Wealth Management Services LLC now owns 793 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 258 shares during the period. Capital City Trust Co. FL raised its position in Pfizer by 6.9% in the 4th quarter. Capital City Trust Co. FL now owns 5,139 shares of the biopharmaceutical company’s stock worth $224,000 after purchasing an additional 330 shares during the period. Legacy Financial Advisors Inc. raised its position in Pfizer by 5.5% in the 4th quarter. Legacy Financial Advisors Inc. now owns 6,593 shares of the biopharmaceutical company’s stock worth $288,000 after purchasing an additional 343 shares during the period. Finally, Acropolis Investment Management LLC raised its position in Pfizer by 3.6% in the 4th quarter. Acropolis Investment Management LLC now owns 10,149 shares of the biopharmaceutical company’s stock worth $443,000 after purchasing an additional 350 shares during the period. Institutional investors own 69.53% of the company’s stock.
Shares of PFE opened at $41.71 on Monday. The stock has a market cap of $251.63 billion, a PE ratio of 13.90, a P/E/G ratio of 2.55 and a beta of 0.75. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.33 and a current ratio of 1.57. Pfizer Inc. has a 1-year low of $34.37 and a 1-year high of $46.47.
In other news, insider Rady A. Johnson sold 8,700 shares of the business’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $41.13, for a total transaction of $357,831.00. Following the completion of the transaction, the insider now directly owns 59,797 shares of the company’s stock, valued at $2,459,450.61. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mikael Dolsten sold 149,553 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $43.55, for a total transaction of $6,513,033.15. Following the transaction, the insider now directly owns 390,097 shares of the company’s stock, valued at $16,988,724.35. The disclosure for this sale can be found here. Insiders have sold 332,526 shares of company stock worth $14,346,539 in the last three months. 0.09% of the stock is currently owned by insiders.
A number of equities research analysts have issued reports on the stock. Zacks Investment Research raised shares of Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, April 10th. Bank of America raised their price target on shares of Pfizer from $45.00 to $48.00 and gave the stock a “buy” rating in a report on Monday, April 1st. Citigroup reaffirmed a “neutral” rating and set a $41.00 target price on shares of Pfizer in a research note on Wednesday, February 20th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $53.00 target price on shares of Pfizer in a research note on Tuesday, February 19th. Finally, Argus raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $55.00 target price on the stock in a research note on Thursday, January 31st. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and seven have assigned a buy rating to the stock. Pfizer has a consensus rating of “Hold” and a consensus price target of $45.61.
TRADEMARK VIOLATION WARNING: This article was originally published by WKRB News and is the property of of WKRB News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.wkrb13.com/2019/04/15/strategic-family-wealth-counselors-l-l-c-buys-shares-of-175608-pfizer-inc-pfe.html.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Story: How to calculate compound interest
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.